S
Shanghai Bangyao Biotechnology
Through innovation led by gene editing, develop breakthrough human therapeutics and benefit the whole world
About Shanghai Bangyao Biotechnology
Shanghai Bangyao Biotechnology Co., Ltd. (BRL Medicine), established in 2013 by co-founders Wu Yuxuan, Li Dali, and Du Bing, is a clinical-stage biopharmaceutical firm headquartered in Minhang, Shanghai. The company concentrates on the development of cell and gene therapies aimed at treating cancers, genetic diseases, and autoimmune disorders. Its establishment was followed by a significant milestone in 2016 with its recombination and the creation of the "Shanghai Research Center for Gene Editing and Cell Therapy" in partnership with a university, solidifying its research foundation.
The company's business revolves around its robust research and development pipeline, leveraging CRISPR-Cas9 gene-editing technology to create novel treatments. BRL Medicine's strategy includes initiating multiple Investigator-Initiated clinical Trials (IIT) in prominent Chinese hospitals to validate its therapies. As a venture capital-backed, privately held company, its financial model relies on securing funding from institutional investors to advance its pipeline through preclinical and clinical stages. To date, the company has raised $55.6M and is backed by investors such as the Free Trade Zone Fund, Xiaomiao Langcheng, and CSPC Pharmaceutical Group.
BRL Medicine has developed five core technology platforms with independent intellectual property rights: the Gene Editing Technology Innovation Platform (CRISTARS®), Hematopoietic Stem Cell Platform, Quikin CAR-T Platform (Quikin CART®), Universal Cell Platform (TyUCell®), and an Enhanced T Cell Platform. These platforms are the engine for its product development, which includes therapies for beta-thalassemia and various cancers. For instance, its CRISTARS® platform is dedicated to creating advanced DNA base editing tools, while the TyUCell® platform focuses on allogeneic immune cells to create generalized, cost-effective cell therapy products. The company has successfully advanced several projects, with five receiving IND approvals and numerous publications in high-impact journals like Nature Medicine and Nature Biotechnology, detailing excellent clinical results for its gene editing projects for β-thalassemia and CAR-T therapies.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2024 | $28M | $110M | CSPC · Betta Biomedical Industry Fund | ↗ |
| SERIES BOther financing | Nov 2022 | $28M | $110M | Gopher Asset Management · Tasly Capital · Oriental Fortune Capital · Betta Biomedical Industry Fund | ↗ |
Growth signals
Latest recorded traffic for Shanghai Bangyao Biotechnology is 1.3K monthly website visits, up 0% over the last three months. Shanghai Bangyao Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Bangyao Biotechnology in the Minhang District ecosystem
The Shanghai Bangyao Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- FFFTZ Fund
Gopher Asset Management
Tasly Capital
Oriental Fortune Capital- BFBetta Biomedical Industry Fund
CSPC
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Bangyao Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Bangyao Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










